Royalty Pharma and Cytokinetics Announce Expanded Strategic
Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO,...
Source: globenewswire.com
Fadyi Malik News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Fadyi Malik. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Fadyi Malik Today - Breaking & Trending Today
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
22.05.2024 - Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) - Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, ... Seite 1
Source: wallstreet-online.de
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
SOUTH SAN FRANCISCO, Calif., May 17, 2024 -- Cytokinetics, Incorporated announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium...
Source: marketscreener.com
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension ...
SOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten
Source: eagletribune.com
Positive Topline Results for SEQUOIA-HCM Trial in OHCM
Preliminary results of the pivotal phase 3 trial show benefit of the cardiac myosin inhibitor, aficamten, in obstructive hypertrophic cardiomyopathy.
Source: medscape.com